Ketamine for Treatment-Resistant Bipolar Depression: What a New 2026 Trial Really Found

Royalty-free supporting image from Pexels.

Bipolar disorder is often associated in the public mind with mania or dramatic mood elevation. Yet for many people living with bipolar I or bipolar II disorder, depressive episodes can be prolonged, disabling, and especially difficult to treat.

When standard evidence-based medications have not provided enough relief, patients and clinicians may face a frustrating question: what comes next?

A randomized clinical trial published online in JAMA Psychiatry on September 2, 2026 offers new evidence about one possible option. Researchers tested a short course of intravenous, or IV, ketamine in adults with treatment-resistant bipolar depression.

The results were encouraging, but the details matter—especially because ketamine is a medically supervised intervention with important safety considerations.

What researchers actually tested

The Ket-BD trial was a double-blind, randomized clinical trial conducted at three sites in Ontario, Canada. Sixty-eight adults between ages 21 and 65 with bipolar I or bipolar II disorder and a current moderate-to-severe depressive episode were randomized to receive either ketamine or midazolam, an active comparison medication.

Participants had previously experienced at least two unsuccessful trials of evidence-based pharmacotherapy.

Participants received four 40-minute intravenous infusions over two weeks. Ketamine was given at 0.5 to 0.75 mg/kg, while midazolam was administered at 0.02 to 0.03 mg/kg.

One detail is especially important: ketamine was used as an adjunctive treatment. Participants remained on a stable dose of at least one mood stabilizer or antipsychotic during the study. This was not ketamine used alone, and it was not unsupervised ketamine use.

What the trial found

At day 14, depressive symptoms measured using the Montgomery-Åsberg Depression Rating Scale, or MADRS, were significantly lower in the ketamine group than in the midazolam group.

After researchers adjusted for sex, type of bipolar disorder, and baseline depression severity, the difference between the groups was 7.3 MADRS points in favor of ketamine. The reported effect size was considered moderate to large.

Safety was particularly important because clinicians have historically been concerned that some antidepressant interventions could contribute to mania or mood destabilization in people with bipolar disorder.

During this short trial, researchers reported no cases of mania, hypomania, psychosis, or suicide attempts in either group. One participant in each group developed mixed features involving subthreshold hypomanic symptoms.

These findings are reassuring within the boundaries of this study. They do not prove that ketamine carries no risk of mania, psychosis, or other complications in larger populations or with longer treatment.

What this study does NOT mean

A promising clinical trial can quickly turn into an oversimplified headline: “ketamine works for bipolar depression.” That statement leaves out several important qualifications.

First, this was a relatively small study. Sixty-eight participants were randomized, and 63 were included in the final efficacy analysis.

Second, the main treatment period lasted only two weeks. That means the study cannot answer every question about long-term effectiveness, maintenance treatment, recurrence of symptoms, or uncommon adverse effects.

It also does not mean ketamine is appropriate for every person with bipolar depression.

Participants met specific study criteria, received treatment in controlled clinical settings, were monitored by professionals, and remained on a mood stabilizer or antipsychotic.

A person's diagnosis, medical history, medications, substance-use history, cardiovascular health, current symptoms, and other risk factors can influence whether a treatment is appropriate.

Finally, these findings should not be interpreted as support for recreational or unsupervised ketamine use. The treatment studied involved carefully calculated intravenous doses administered within a medical research protocol.

Royalty-free supporting image from Pexels.

Why bipolar depression requires careful diagnosis

Depression can look similar across different diagnoses. Low mood, loss of interest, fatigue, sleep changes, concentration problems, hopelessness, and changes in appetite can occur in both major depressive disorder and bipolar depression.

What can change the clinical picture is a person's broader history. Clinicians may ask about previous periods of unusually elevated or irritable mood, reduced need for sleep, increased energy, impulsivity, racing thoughts, unusually increased activity, or other symptoms associated with mania or hypomania.

That distinction matters because treatment planning can differ.

This is one reason a psychiatric evaluation should look beyond the symptoms someone is experiencing today and consider previous mood episodes, family history, medication responses, sleep patterns, substance use, medical conditions, and changes over time.

What patients should take away from this research

For someone who has tried multiple treatments without adequate relief, new research can bring hope. It can also create pressure to immediately pursue the newest intervention.

A more useful approach is to bring the research into a conversation with a qualified psychiatric clinician who can place the findings in the context of your individual history.

Ketamine is one area of active psychiatric research. It is not a replacement for a comprehensive treatment plan.

Depending on the individual, treatment for bipolar depression may involve mood stabilizers, certain antipsychotic medications, psychotherapy, attention to sleep and daily routine, treatment of substance-use concerns, attention to physical health, and other evidence-based strategies.

The most useful message from this trial is not that everyone with bipolar depression should receive ketamine. It is that researchers are continuing to study additional options for people whose depression has not responded adequately to established treatments.

When symptoms become urgent

Bipolar depression can sometimes involve suicidal thoughts, severe hopelessness, psychosis, inability to care for oneself, or rapidly changing mood symptoms.

If you or someone you know is in immediate danger, call 911 or go to the nearest emergency department. In the United States, you can also call or text 988 to reach the Suicide & Crisis Lifeline.

A blog article or routine outpatient appointment is not a substitute for emergency care.

Sources & References

1. Orsini DK, Di Luch S, Tomlinson G, et al. Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial. JAMA Psychiatry. Published September 2, 2026. doi:10.1001/jamapsychiatry.2026.2658.
2. PubMed. PMID 42684694.
3. University Health Network Research. A New Avenue for Bipolar Depression. September 2, 2026.

This article is for educational purposes only. Ketamine is a prescription medical treatment requiring appropriate clinical evaluation and supervision. This information does not replace individualized medical or psychiatric advice.